Clinical trials: Neoplasms, Hematopoietic
Hematopoietic Stem Cell Transplant
Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing…
- Trial name
- NCT05945121
- Testing
- Cardio-oncology program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Michigan Rogel Cancer Center
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth
This study evaluates the effects of the Survivorship Wellness Group Program following active treatment, as well as to learn from Survivorship Wellness participants about their concerns regarding the current COVID-19 pandemic.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04630015
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- University of California, San Francisco
Multiple Myeloma, Non-Hodgkin Lymphoma
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia
- Trial name
- NCT01343368
- Testing
- Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematologic Malignancies
Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
Primary: Define the maximal tolerated dose (MTD) of VNP40401M when given with hematopoietic cell transplantation (HCT) Secondary: Describe the change in pharmacokinetic (PK) parameters with increasing doses of drug.
- Trial name
- NCT00521859
- Testing
- Cloretazine, Fludarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Graft Vs Host Disease, Graft-versus-host-disease
TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant
The CliniMACS® device is FDA-approved only for one indication (CD34+ selection). Additional use of this device outside of this indication requires the use of feasibility studies.
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT05968170
- Testing
- CliniMACS® device
- Sponsor
- Neena Kapoor, M.D.
Stem Cell Transplantation, Immunotherapy
Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell Therapy
Hematopoietic Stem Cell Transplantation (HSCT) and CAR T-cell therapy are effective treatments for blood cancers, extending patients lives. However, these treatments can cause side effects like muscle weakness and fatigue.
- Conditions
- Stem Cell Transplantation, Immunotherapy, CAR T-Cell Therapy
- Trial name
- HEMATOneeds (NCT06506396)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Modena and Reggio Emilia
Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers
This clinical trial evaluates how propionate and butyrate supplementation alters intestinal health in healthy volunteers and whether it would be feasible to administer these supplements to patients undergoing allogeneic…
- Conditions
- Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT07611370
- Testing
- Biospecimen Collection, Microencapsulated Sodium Butyrate, Microencapsulated Sodium Propionate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Familial Platelet Disorder With Associated Myeloid Malignancy
Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder
This phase I trial studies the safety and side effects of low-dose sirolimus in treating patients with RUNX1 familial platelet disorder (FPD).
- Trial name
- NCT07844694
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- OHSU Knight Cancer Institute
B-Cell Lymphomas
Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
The aim of this study is rate of acute graft-versus-host disease II-IV measured at day +365according to conventional criteria (Przepiorka et al.
- Trial name
- NCT01613300
- Testing
- Ofatumumab
- Where
- 10 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
This randomized phase III trial is studying how well Caphosol rinse works in preventing mucositis in young patients undergoing autologous or donor stem cell transplant.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT01305200
- Testing
- supersaturated calcium phosphate rinse, questionnaire administration, quality-of-life assessment
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 226 people
- Sponsor
- Children's Oncology Group
Lymphocytic Leukemia
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling molecules needed for cell growth. Monoclonal antibodies, such as alemtuzumab, can bind to and kill malignant lymphocytes.
- Trial name
- NCT00935792
- Testing
- alemtuzumab, everolimus
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Cytomegaloviral Infection, Hematopoietic and Lymphoid System Neoplasm
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This phase Ib trial evaluates the safety and most effective dose of a cytomegalovirus (CMV) pp65 peptide-loaded alpha-type-1 polarized dendritic cell (CMV-alphaDC1) vaccination in patients who are undergoing an allogeneic…
- Trial name
- NCT05589844
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Bone Marrow Transplant, Information Disclosure
Effects of Digital Stories Intervention on Psychosocial Well-being
Patients and caregivers undergoing hematopoietic stem cell transplantation often continue to experience anxiety, depression, isolation, and other psychosocial distress.
- Conditions
- Bone Marrow Transplant, Information Disclosure, Hematopoietic Stem Cell Transplantation, Psychosocial Health
- Trial name
- NCT03654599
- Testing
- Baseline Surveys, Digital Stories Intervention, Information Control Intervention
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Arizona State University
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Inqovi Maintenance Therapy in Myeloid Neoplasms
This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant.
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia
- Trial name
- NCT04980404
- Testing
- Inqovi
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Hematologic Malignancies, Other Diagnoses, Comorbidities, and Complications
Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life
We are interested in studying whether and how medical problems other than primary cancer before hematopoietic cell transplantation would impact the profiles of quality of life and toxicities post-transplantation for patients with…
- Trial name
- NCT01930981
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
Background: Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells) have been used with varying degrees of success as an immune therapy for blood-system cancers (leukemias, myelodysplastic…
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Hodgkins Lymphoma
- Trial name
- NCT01326728
- Testing
- Allogeneic stem cell transplant
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma, Head and Neck Cancer
Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
The overall goal of this study is to develop a pre-clinical platform of melanoma and head and neck squamous cell cancer that will allow the investigators to learn more about these diseases and discover better and more…
- Trial name
- NCT02331134
- Testing
- Filgrastim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm
Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma
This phase 2 trial tests the safety and effectiveness of a cancer vaccine called LabVax 3(22)-23 and GM-CSF in combination with pembrolizumab in treating adenocarcinoma that has spread to other places in the body (advanced…
- Trial name
- NCT07859592
- Testing
- LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
Multiple Myeloma
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT).
- Trial name
- NCT05065047
- Testing
- Belantamab mafodotin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Acute Myeloid Leukemia
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
The purpose of this study is to see whether hematopoietic stem cell transplant (HSCT) patients can consistently eat a diet rich in prebiotics.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
- Trial name
- HCTDiet (NCT04629430)
- Testing
- Pre-biotic foods/drinks
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia